ENDO 2025
Crinetics Showcases the Next Generation of Endocrinology Innovation at ENDO 2025
“ENDO 2025 will be an incredibly meaningful moment for Crinetics
and our mission to be the premier endocrine-focused global pharmaceutical company.”
– Scott Struthers, Ph.D., Founder & CEO
Presentations
PALSONIFY™ (paltusotine) Presentations:
Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension
Paltusotine Results in Improved Symptom Stability in Biochemically Controlled Acromegaly
Effects of Paltusotine Treatment on Patient-Reported Symptoms of Acromegaly in Phase 3 Randomized Placebo-Controlled Studies (PATHFNDR-2 and PATHFNDR-1)
Once-Daily Oral Paltusotine in the Treatment of Patients With Biochemically Uncontrolled Acromegaly: Interim Results of the PATHFNDR-2 Open-Label Extension
Atumelnant Presentations
Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study
Once Daily Oral Atumelnant (CRN04894) Induces Rapid, Substantial, and Sustained Reductions of Androstenedione and 17-Hydroxyprogesterone in Adults With Classical Congenital Adrenal Hyperplasia: Interim Results From a 12-Week, Phase 2, Open-Label Study
Rapid and Sustained Reduction of 11-Oxygenated Androgens in Adults With Classic Congenital Adrenal Hyperplasia Following Once-Daily Oral Atumelnant (CRN04894): Results From a 12-Week, Phase 2, Open-Label Study
Early Pipeline Presentations
Discovery and Characterization of an Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonist for the Treatment of Graves’ Disease and Thyroid Eye Disease
Exploring new frontiers with our science to expand patient reach
Our in-house R&D team of proven drug hunters develops transformative novel molecules with a focus on the endocrine system and G-protein coupled receptors. Our pipeline is purposefully created to deliver innovative therapies.
Live from ENDO 2025
Live from ENDO 2025 with Dr. Raffaella Colzani
07/15/2025
Live from ENDO2025: Dr. Raffaella Colzani shares how receptor biology is opening new doors.
Live from ENDO 2025 with Dr. Robert Cuddihy
07/15/2025
Live from ENDO2025: What’s changing in endocrinology — and why now? Dr. Bob Cuddihy shares his take on where endocrinology is headed, and how patient voices are shaping clinical development in new ways.
Live from ENDO 2025 with Dr. Antonio Ribeiro-Oliveira Jr
07/14/2025
Live from ENDO2025: Cushing’s is complex — Dr. Antonio Ribeiro-Oliveira, Jr. explains why. Hear his candid look at a complex condition.
Live from ENDO 2025 with Dr. Peter Trainer
07/13/2025
Live from ENDO2025: What’s misunderstood about adrenal and pituitary disorders — and why does it matter? Dr. Peter Trainer shares insights on the real-world challenges of managing adrenal and pituitary disorders and where the field still has room to grow.
Live from ENDO 2025 with Dr. Alan Krasner
07/13/2025
Live from ENDO2025: Where is endocrinology heading next? Dr. Alan Krasner breaks it down for us, from the science and strategy to what really matters in long-term care.